Published in J Neurosurg on July 01, 1988
Neurocysticercosis: a review. ScientificWorldJournal (2012) 2.17
Neurocysticercosis. Postgrad Med J (1998) 0.93
Neurocysticercosis, meningioma, and silent corticotroph pituitary adenoma in a 61-year-old woman. Case Rep Pathol (2012) 0.75
The course of seizures after treatment for cerebral cysticercosis. N Engl J Med (1992) 2.77
Therapy of parenchymal brain cysticercosis with praziquantel. N Engl J Med (1984) 2.58
Neurocysticercosis: an update. Rev Infect Dis (1989) 2.39
A proposal to declare neurocysticercosis an international reportable disease. Bull World Health Organ (2000) 2.11
Neurocysticercosis: a new classification based on active and inactive forms. A study of 753 cases. Arch Intern Med (1985) 2.08
ELISA in the diagnosis of neurocysticercosis. Arch Neurol (1986) 1.96
Neurocysticercosis as the main cause of late-onset epilepsy in Mexico. Arch Intern Med (1990) 1.89
Albendazole therapy for giant subarachnoid cysticerci. Arch Neurol (1992) 1.88
Viral infections and IgM autoantibodies to cytoplasmic intermediate filaments. Clin Exp Immunol (1979) 1.88
Albendazole therapy for neurocysticercosis. Arch Intern Med (1987) 1.58
Cysticercotic encephalitis: a severe form in young females. Am J Trop Med Hyg (1987) 1.58
Taenia solium disease in humans and pigs: an ancient parasitosis disease rooted in developing countries and emerging as a major health problem of global dimensions. Microbes Infect (2000) 1.45
Dexamethasone increases plasma levels of albendazole. J Neurol (1990) 1.42
[Spinal arachnoiditis as a complication of peridural anesthesia]. Medicina (B Aires) (1993) 1.40
Immunodiagnosis of neurocysticercosis. Disappointing performance of serology (enzyme-linked immunosorbent assay) in an unbiased sample of neurological patients. Arch Neurol (1992) 1.33
Polymorphic forms of human apolipoprotein[a]: inheritance and relationship of their molecular weights to plasma levels of lipoprotein[a]. J Lipid Res (1990) 1.33
Immunodiagnosis of human cysticercosis in cerebrospinal fluid. Antigens from murine Taenia crassiceps cysticerci effectively substitute those from porcine Taenia solium. Arch Pathol Lab Med (1990) 1.26
Autoantibodies against axonal neurofilaments in patients with Kuru and Creutzfeldt-Jakob disease. Science (1980) 1.25
Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. Neurology (1987) 1.25
Therapy for neurocysticercosis: a reappraisal. Clin Infect Dis (1993) 1.24
Hydrocephalus secondary to cysticercotic arachnoiditis. A long-term follow-up review of 92 cases. J Neurosurg (1987) 1.18
Intramedullary cysticercosis cured with drug treatment. A case report. Spine (Phila Pa 1976) (1996) 1.17
Sex-related severity of inflammation in parenchymal brain cysticercosis. Arch Intern Med (1988) 1.16
O-Glycosylation in sprouting neurons in Alzheimer disease, indicating reactive plasticity. J Neuropathol Exp Neurol (2001) 1.16
Epilepsy in the tropics: II. Clinical presentations, pathophysiology, immunologic diagnosis, economics, and therapy. Epilepsia (1996) 1.15
Isolation, purification, and partial characterization of type V-A hemagglutinin from Escherichia coli GV-12, O1:H-. J Bacteriol (1982) 1.11
Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob Agents Chemother (2000) 1.06
Differential diagnosis between ventriculitis and fourth ventricle cyst in neurocysticercosis. J Neurosurg (1983) 1.05
Praziquantel in the treatment of neurocysticercosis: long-term follow-up. Neurology (1985) 1.04
Method for preparing cultures of central neurons: cytochemical and immunochemical studies. Proc Natl Acad Sci U S A (1980) 1.03
Cysticercosis. Clinical classification based on imaging studies. Arch Intern Med (1997) 1.02
AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br J Cancer (2001) 1.01
Epilepsy in the tropics: I. Epidemiology, socioeconomic risk factors, and etiology. Epilepsia (1996) 1.00
Total recovery of visual function after treatment for cerebral cysticercosis. N Engl J Med (1991) 0.98
Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer (2005) 0.98
Single-day praziquantel therapy for neurocysticercosis. N Engl J Med (1996) 0.97
Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens (1999) 0.97
Plasma and CSF levels of albendazole and praziquantel in patients with neurocysticercosis. Clin Neuropharmacol (1990) 0.97
Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine. Eur J Cancer (1998) 0.96
Neurocysticercosis: validity of ELISA after storage of whole blood and cerebrospinal fluid on paper. Trop Med Int Health (2001) 0.96
Ophthalmoplegic polyneuropathy associated with infectious mononucleosis. Ann Neurol (1983) 0.95
Effects of pentoxifylline or dexamethasone in combination with amphotericin B in experimental murine cerebral cryptococcosis: evidence of neuroexcitatory pathogenic mechanisms. Antimicrob Agents Chemother (1996) 0.93
Single dose antibiotic therapy is not as effective as conventional regimens for management of acute urinary tract infections in children. Pediatr Infect Dis J (1988) 0.93
Domestic violence in Mexico. JAMA (1996) 0.92
Heterogeneic autoantibody against neurofilament protein in the sera of animals with experimental kuru and Creutzfeldt-Jakob disease and natural scrapie infection. Infect Immun (1982) 0.92
Mechanisms of smooth muscle antibody production: a clinical study in children with infections, haemolytic syndromes, and idiopathic thrombocytopenic purpura. J Clin Pathol (1979) 0.92
Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease. Neurosci Lett (1999) 0.92
A new complement fixation test for the diagnosis of neurocysticercosis in cerebrospinal fluid. J Neurol (1991) 0.92
Identification of galectin-3 and mucin-type O-glycans in breast cancer and its metastasis to brain. Cancer Invest (2008) 0.91
Storage of cerebrospinal fluid on paper. Lancet (1989) 0.90
Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis. Br J Cancer (2008) 0.90
Smooth muscle autoantibodies reacting with cytoplasmic intermediate filaments in sera from normal, nonimmunized rabbits. Clin Immunol Immunopathol (1980) 0.89
Longitudinal spinal cord sections as substratum for anti-neurofilament antibody detection. J Neurol Sci (1982) 0.89
Albendazole therapy for subarachnoid and ventricular cysticercosis. Case report. J Neurosurg (1990) 0.88
Brain tumors in Mexico: characteristics and prognosis of glioblastoma. Surg Neurol (2000) 0.88
Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol Scand (1990) 0.88
Cellular distribution of insulin-like growth factor-II/mannose-6-phosphate receptor in normal human brain and its alteration in Alzheimer's disease pathology. Neurobiol Aging (2005) 0.87
Effect of anticysticercal treatment on the prognosis of epilepsy in neurocysticercosis: a pilot trial. Epilepsia (1994) 0.87
Cryptococcus neoformans var. gattii among patients with cryptococcal meningitis in Mexico. First observations. Mycopathologia (1996) 0.87
Immunogenetic profile of multiple sclerosis in Mexicans. Hum Immunol (1986) 0.87
Intestinal malabsorption in macroglobulinemia. Am J Dig Dis (1971) 0.87
Distribution of actin and myosin in muscle and non-muscle cells. Cell Tissue Res (1979) 0.86
Cefotaxime vs. conventional therapy for the treatment of bacterial meningitis of infants and children. Pediatr Infect Dis (1986) 0.86
Cysticercosis: towards the design of a diagnostic kit based on synthetic peptides. Immunol Lett (2000) 0.86
Antigens from Taenia crassiceps cysticerci used in complement fixation, enzyme-linked immunosorbent assay, and western blot (immunoblot) for diagnosis of neurocysticercosis. J Clin Microbiol (1995) 0.86
Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Antimicrob Agents Chemother (1997) 0.86
Dengue virus infects mouse cultured neurons but not astrocytes. J Med Virol (1994) 0.86
Differences between ventricular and lumbar cerebrospinal fluid in hydrocephalus secondary to cysticercosis. Neurosurgery (1995) 0.85
Possible relationship between neurocysticercosis and hematological malignancies. Arch Med Res (1999) 0.85
Cardiac arrhythmias in experimental subarachnoid hemorrhage. Stroke (1977) 0.85
MR imaging in cysticercotic encephalitis. AJNR Am J Neuroradiol (1989) 0.85
Effect of propranolol on sympathetic nervous activity in hydrallazine-treated hypertensive patients. Br J Clin Pharmacol (1978) 0.84
Retinoic acid increases tissue and plasma contents of nerve growth factor and prevents neuropathy in diabetic mice. Eur J Clin Invest (2005) 0.83
Immunodominant synthetic peptides of Taenia crassiceps in murine and human cysticercosis. Immunol Lett (1996) 0.83
Optimization of the single-day praziquantel therapy for neurocysticercosis. Neurology (2001) 0.83
C6 rat glioma grown into the peritoneal cavity, a large source of tumoral cells for subcutaneous transplant of glioma. J Neurooncol (1999) 0.83
Population-based surveillance and a case-control study of risk factors for endemic lymphocutaneous sporotrichosis in Peru. Clin Infect Dis (2002) 0.83
Comparative study of cefprozil and cefaclor in children with bacterial infections of skin and skin structures. Pediatr Infect Dis J (1992) 0.83
Relationship between maize stem structural characteristics and resistance to pink stem borer (Lepidoptera: Noctuidae) attack. J Econ Entomol (2003) 0.82
What is the significance of the presence of MHC molecules on the surface of parasites in human neurocysticercosis? J Immunogenet (1989) 0.82
Low contents of nerve growth factor in serum and submaxillary gland of diabetic mice. A possible etiological element of diabetic neuropathy. J Neurol Sci (1994) 0.82
Isolation, quantitation, and characterization of a stable complex formed by Lp[a] binding to triglyceride-rich lipoproteins. J Lipid Res (2001) 0.82
[Frequency of brain tumors in epileptic patients]. Salud Publica Mex (1982) 0.82
Protective effect of pentoxifylline plus thalidomide against septic shock in mice. Int J Exp Pathol (1999) 0.82
Immunoperoxidase EM localisation of cytoplasmic actin in cultured fibroblasts. J Immunol Methods (1980) 0.81
Plasma proteins as indices of response to nutritional therapy in cancer patients. J Surg Oncol (1985) 0.81
Sensitive high-performance liquid chromatographic assay for albendazole and its main metabolite albendazole sulphoxide in plasma and cerebrospinal fluid. J Chromatogr (1989) 0.81
Is the frequency of multiple sclerosis increasing in Mexico? J Neurol Neurosurg Psychiatry (1995) 0.81
Identification of a particular B cell alloantigen associated with susceptibility to lepromatous leprosy. Lepr Rev (1981) 0.81
Effects of prednisone on ventriculoperitoneal shunt function in hydrocephalus secondary to cysticercosis: a preliminary study. J Neurosurg (1996) 0.81
Pt/TiO2 brain biocompatible nanoparticles: GBM treatment using the C6 model in Wistar rats. Acta Biomater (2008) 0.81
Clinical pharmacokinetics of albendazole in patients with brain cysticercosis. J Clin Pharmacol (1992) 0.81
Sensitivity and specificity of ELISA and immunoblot for diagnosing neurocysticercosis. Eur J Clin Microbiol Infect Dis (2002) 0.81
Possible association between Taenia solium cysticercosis and cancer: increased frequency of DNA damage in peripheral lymphocytes from neurocysticercosis patients. Trans R Soc Trop Med Hyg (2000) 0.81
Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer. Neurology (2011) 0.81
Sialic acid content of human low density lipoproteins affects their interaction with cell receptors and intracellular lipid accumulation. J Lipid Res (1992) 0.81
Ultrastructural changes in limb distal nerves of rats with alcoholism and/or malnutrition before and after dietary correction. J Appl Toxicol (1998) 0.80
Immunoglobulins in epilepsy. J Neurol Sci (1982) 0.80
Genetic pattern of the HLA system: HLA A, B, C, DR, and DQ antigens in Mexican patients with parenchymal brain cysticercosis. Hum Biol (1991) 0.80
[A short praziquantel regimen for the treatment of parenchymatous neurocysticercosis]. Gac Med Mex (1999) 0.79